Half-year liquidity contract statement signed between Median Technologies and AUREL BGC
Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account at June 30, 2018:
- € 131,204.47
- 31,040 shares
For information, at December 31, 2017, the following resources were listed in the liquidity account:
- € 205,848.52
- 20,981 shares
About Median Technologies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2017-2018. Median Technologies has been awarded the 2018 Tech 40 Label, has joined the EnterNext Tech 40 Index and is a winner of the Deloitte Technology Fast 500™ 2017 EMEA program. Median is a member of the Bpifrance Excellence Network.
Sen. Dir., Corporate Communications
+33 6 10 93 58 88
+33 1 56 88 11 11
Alizé RP (Press)
+33 1 44 54 36 66